MilliporeSigma Cell & Gene Tech Expo August 2025: Gene Therapy

Adeno-associated virus (AAV) has emerged as a leading vector for treating life-threatening genetic diseases, driving a surge in demand for high-titer AAV therapeutics. Achieving these high titers requires careful selection of transfection reagents, optimization of experimental conditions, and strategic post-transfection feeding. PEI (polyethylenimine) remains a widely used transfection reagent, and MilliporeSigma has successfully optimized PEI-based protocols across various cell lines, serotypes, and genes of interest to maximize yields. Additionally, the commercially available Cellvento® ModiFeed Prime has demonstrated significant titer improvements across multiple cell lines and serotypes, though results may vary depending on the process.

Expanding beyond PEI, MilliporeSigma now offers non-PEI transfection solutions from Mirus Bio, including TransIT-VirusGEN® + RevIT® AAV Enhancer and the TransIT®-AAViator System. These reagents have shown remarkable results, achieving titers up to two logs higher than PEI-based methods—without requiring transfection optimization.

Explore tailored solutions that drive efficiency, scalability, and innovation to elevate your AAV production.